{"id":390527,"date":"2018-12-12T00:00:00","date_gmt":"2018-12-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreon0014-2018-biopharma-non-small-cell-lung-cancer-access-and-reimbursement-us-2018\/"},"modified":"2026-03-31T10:47:38","modified_gmt":"2026-03-31T10:47:38","slug":"acreon0014-2018-biopharma-non-small-cell-lung-cancer-access-and-reimbursement-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreon0014-2018-biopharma-non-small-cell-lung-cancer-access-and-reimbursement-us-2018\/","title":{"rendered":"Non-Small-Cell Lung Cancer | Access and Reimbursement | US | 2018"},"content":{"rendered":"<p>The high number of premium-priced <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> therapies and the large number of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> patients result in significant financial burden for payers. These costs are set to increase with the approval of additional therapies, such as AstraZeneca\u2019s Imfinzi for unresectable stage III <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>, and with label expansions of existing treatments, such as AstraZeneca\u2019s Tagrisso in first-line <em><abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>&#8211;<\/em>mutation-positive <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>. To control the rising costs of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> treatment, payers employ extensive utilization management strategies. Presenting data from surveys of 31 <abbr title=\"managed care organization\">MCO<\/abbr>s and 102 oncologists, this access and reimbursement content analyzes the reimbursement environment for eight of the major new therapies for metastatic <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>, and how <abbr title=\"managed care organization\">MCO<\/abbr> formulary decisions and utilization controls on both the pharmacy benefit and medical benefit affect prescribing by surveyed oncologists.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How do <abbr title=\"managed care organization\">MCO<\/abbr>s undergo formulary inclusion decisions upon new <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> drug launches? What are the <abbr title=\"pricing and reimbursement\">P&#038;R<\/abbr> drivers and constraints for <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> drugs?<\/li>\n<li>What is the coverage status of the major <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> drugs and what are the key drivers behind these decisions? What changes are planned for the future?<\/li>\n<li>What utilization management strategies are employed by payers to control the cost of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> agents? How do they assess the cost and efficacy impact of new and existing <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> therapies?<\/li>\n<li>How do physicians prescribe existing <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> therapies? What are their restrictions, as well as the clinical and nonclinical drivers for their decisions, and what is the dynamic interplay between them?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Access &#038; Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.<\/p>\n<p><strong>Markets covered: <\/strong>United States<\/p>\n<p><strong>Primary research:<\/strong><\/p>\n<ul>\n<li>Survey of 102 medical oncologists in the United States.<\/li>\n<li>Survey of 31 U.S. managed care organization (<abbr title=\"managed care organization\">MCO<\/abbr>) pharmacy and medical directors (<abbr title=\"pharmacy director\">PD<\/abbr>s\/<abbr title=\"medical director\">MD<\/abbr>s).<\/li>\n<\/ul>\n<p><strong>Key drugs covered: <\/strong>Opdivo, Keytruda, Tecentriq, Imfinzi, Alecensa, Xalkori, Tagrisso, Tarceva.<\/p>\n","protected":false},"template":"","class_list":["post-390527","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390527\/revisions"}],"predecessor-version":[{"id":576674,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390527\/revisions\/576674"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}